Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-Day Assessment of Vestipitant for Primary Insomnia
2008-006345-72Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Insomnia comparing Vestipitant 15 mg with Placebo (2 arms). Primary endpoint: Wake after sleep onset (WASO) at Days 27/28. Started Feb 2009; status: completed.
02
Drugs
vestipitant
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2008-006345-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006345-72.